Richard Cunningham
Chief Executive Officer chez ANEBULO PHARMACEUTICALS, INC.
Profil
Richard Anthony Cunningham currently works at Icagen-T, Inc., as President, Chief Executive Officer & Director and Anebulo Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2023.
Mr. Cunningham also formerly worked at Icagen, Inc., as President, Chief Executive Officer & Director in 2020 and Tyme Technologies, Inc., as Chief Executive Officer & Director from 2020 to 2022.
Postes actifs de Richard Cunningham
| Sociétés | Poste | Début |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Chief Executive Officer | 05/10/2023 |
Icagen-T, Inc.
 Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Chief Executive Officer | - |
Anciens postes connus de Richard Cunningham
| Sociétés | Poste | Fin |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Chief Executive Officer | 16/09/2022 |
Icagen, Inc.
 Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Chief Executive Officer | 01/11/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Icagen, Inc.
Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Icagen-T, Inc.
Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Health Technology |
